KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBITDA (2016 - 2026)

Edwards Lifesciences has reported EBITDA over the past 17 years, most recently at $151.1 million for Q4 2025.

  • For Q4 2025, EBITDA fell 51.66% year-over-year to $151.1 million; the TTM value through Dec 2025 reached $1.3 billion, down 8.3%, while the annual FY2025 figure was $1.3 billion, 8.3% down from the prior year.
  • EBITDA for Q4 2025 was $151.1 million at Edwards Lifesciences, down from $307.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $542.1 million in Q2 2021 and troughed at $151.1 million in Q4 2025.
  • A 5-year average of $359.8 million and a median of $370.4 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: surged 419.45% in 2021 and later crashed 51.66% in 2025.
  • Year by year, EBITDA stood at $374.4 million in 2021, then plummeted by 47.2% to $197.7 million in 2022, then surged by 75.42% to $346.8 million in 2023, then dropped by 9.86% to $312.6 million in 2024, then crashed by 51.66% to $151.1 million in 2025.
  • Business Quant data shows EBITDA for EW at $151.1 million in Q4 2025, $307.1 million in Q3 2025, and $411.2 million in Q2 2025.